LeadIQ logo
Learn more at LeadIQ.com

Insights

LicenseOpportunity Current corporate structure shows Urovant Sciences is now Sumitomo Pharma America with past asset divestments and licensing activity, indicating potential opportunities to re-engage or partner on existing assets like vibegron or URO-902 through SMPA channels and regional licensing strategies.

Urology Leader Strong focus on urologic patient care and the aim to be a leading specialty company suggests a receptive market for partnerships, co-development, or expansion of urology-focused therapies and digital health solutions that align with their mission.

ProductLaunch GEMTESA launched in 2021 establishes commercial capability in overactive bladder, signaling readiness for additional product introductions or line extensions and potential collaboration on market access, payer strategies, or real-world evidence generation.

FinancialHealth Revenue in the lower-mid tens of millions with a relatively lean headcount and recent headcount reductions, implying efficiency-driven partnerships, milestone-based collaborations, or licensing deals that align with cost-conscious commercial scaling.

StrategicAssets Historical awards and recognition for Phase IIa gene therapy programs (URO-902) and past licensing of vibegron to Pierre Fabre indicate a track record of innovative assets and potential for licensing, co-development, or regional commercialization discussions with SMPA.

Similar companies to Urovant Sciences, Inc.

Urovant Sciences, Inc. Tech Stack

Urovant Sciences, Inc. uses 8 technology products and services including Power BI, Qlik, SAS, and more. Explore Urovant Sciences, Inc.'s tech stack below.

Media & News

Urovant Sciences, Inc.'s Email Address Formats

Urovant Sciences, Inc. uses at least 4 email formats:
Urovant Sciences, Inc. Email FormatsExamplePercentage
First.Last@urovant.comJohn.Doe@urovant.com
92%
Last@urovant.comDoe@urovant.com
5%
FLast@urovant.comJDoe@urovant.com
2%
First.Middle@urovant.comJohn.Michael@urovant.com
1%

Frequently Asked Questions

What is Urovant Sciences, Inc.'s stock symbol?

Minus sign iconPlus sign iconUrovant Sciences, Inc. is a publicly traded company; the company's stock symbol is UROV.

What is Urovant Sciences, Inc.'s official website and social media links?

Minus sign iconPlus sign iconUrovant Sciences, Inc.'s official website is urovant.com and has social profiles on LinkedIn.

How much revenue does Urovant Sciences, Inc. generate?

Minus sign iconPlus sign icon As of July 2026, Urovant Sciences, Inc.'s annual revenue is estimated to be $10M - $25M.

What is Urovant Sciences, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign iconUrovant Sciences, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Urovant Sciences, Inc. have currently?

Minus sign iconPlus sign iconAs of July 2026, Urovant Sciences, Inc. has approximately 201 employees across 3 continents, including North America, Europe and Asia. Key team members include Chief Executive Officer: J. R., Head Of Intellectual Property Records: A. L. and Co-Chair And Founder, Women's Leadership Council Engineer: C. C. Explore Urovant Sciences, Inc.'s employee directory with LeadIQ.

What industry does Urovant Sciences, Inc. belong to?

Minus sign iconPlus sign iconUrovant Sciences, Inc. operates in the Biotechnology Research industry.

What technology does Urovant Sciences, Inc. use?

Minus sign iconPlus sign iconUrovant Sciences, Inc.'s tech stack includes Power BI, Qlik, SAS, Drupal, SAP, New Relic, Adobe Creative Suite and Zoom.

What is Urovant Sciences, Inc.'s email format?

Minus sign iconPlus sign iconUrovant Sciences, Inc.'s email format typically follows the pattern of First.Last@urovant.com. Find more Urovant Sciences, Inc. email formats with LeadIQ.

How much funding has Urovant Sciences, Inc. raised to date?

Minus sign iconPlus sign icon As of July 2026, Urovant Sciences, Inc. has raised $100M in funding. The last funding round occurred on Feb 22, 2019.

When was Urovant Sciences, Inc. founded?

Minus sign iconPlus sign iconUrovant Sciences, Inc. was founded in 2017.
Urovant Sciences, Inc. logo

Urovant Sciences, Inc.

Biotechnology ResearchCalifornia, United States201-500 Employees

Urovant Sciences, Inc. operates in the biotechnology research sector with a focus on urology. Based in Irvine, California, the company develops therapies and pursues licensing opportunities intended to advance urologic patient care. It brought GEMTESA (vibegron) 75 mg tablets to the U.S. market in 2021 for the treatment of overactive bladder, addressing symptoms such as urgency, urgency incontinence, and urinary frequency, and it maintains ongoing research programs, including an investigational gene therapy candidate, URO-902.

The company serves patients and healthcare providers dealing with urologic conditions and aims to be recognized as a leading specialty firm rooted in trust and patient care. Corporate activity includes licensing and asset transactions, such as the exclusive license for vibegron in the European Economic Area that was acquired by Pierre Fabre Group in 2022. Urovant operates as a subsidiary of Sumitovant Biopharma Ltd. and has explored URO-902 in a Phase IIa trial, which earned a Best in Category award for interim data in 2022.

Section iconCompany Overview

Website
urovant.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
UROV
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
201-500

Section iconMedia & News

Section iconFunding & Financials

  • $100M

    Urovant Sciences, Inc. has raised a total of $100M of funding over 1 rounds. Their latest funding round was raised on Feb 22, 2019 as a Debt Financing.

  • $10M - $25M

    Urovant Sciences, Inc.'s revenue is estimated to be in the range of $10M - $25M

Company Leadership

  • Chief Executive Officer at Urovant Sciences, Inc.
    J. R.
    Chief Executive Officer
    Mobile Phone
  • Head Of Intellectual Property Records at Urovant Sciences, Inc.
    A. L.
    Head Of Intellectual Property Records
    Mobile Phone
  • Co-Chair And Founder, Women's Leadership Council Engineer at Urovant Sciences, Inc.
    C. C.
    Co-Chair And Founder, Women's Leadership Council Engineer
    Mobile Phone
  • Area Vice President- Market Access, National And Government Accounts at Urovant Sciences, Inc.
    S. P.
    Area Vice President- Market Access, National And Government Accounts
    Mobile Phone
  • Vice President, Corporate Communications at Urovant Sciences, Inc.
    A. D.
    Vice President, Corporate Communications
    Mobile Phone

Employee Directory

  • Medical Director at Urovant Sciences, Inc.
    A. B.
    Medical Director
    Mobile Phone
  • Associate Director Clinical Research at Urovant Sciences, Inc.
    E. N.
    Associate Director Clinical Research
    Mobile Phone
  • Quality Assurance Quality Control Director at Urovant Sciences, Inc.
    N. B.
    Quality Assurance Quality Control Director
    Mobile Phone
  • Senior Director, Quality at Urovant Sciences, Inc.
    N. O.
    Senior Director, Quality
    Mobile Phone
  • Director Project Management at Urovant Sciences, Inc.
    P. M.
    Director Project Management
    Mobile Phone

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.